Publications by authors named "L Hammershaimb"

Claim this Profile
P
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma.
Stergios J Moschos, Cindy A Sander, Wenjun Wang, Shelley L Reppert, Laura M Drogowski, Luz Hammershaimb

J Immunother· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
Peter Hersey, Jeffrey Sosman, Steven O'Day, Jon Richards, Agop Bedikian, Luz Hammershaimb

Cancer· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.
Deirdre O'Mahony, John C Morris, Maryalice Stetler-Stevenson, Helen Matthews, Margaret R Brown, Luz Hammershaimb

Clin Cancer Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.
Catherine Delbaldo, Eric Raymond, Karina Vera, Luz Hammershaimb, Karen Kaucic

Invest New Drugs· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
Douglas G McNeel, Jens Eickhoff, Fred T Lee, David M King, Dona Alberti, Luz Hammershaimb

Clin Cancer Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis